Table 1 Demographic and clinical characteristics of the patients and healthy control subjects enrolled in the study
From: Thymosin β4 and β10 in Sjögren’s syndrome: saliva proteomics and minor salivary glands expression
pSS (n = 9) | ss/SSc (n = 7) | ss/SLE (n = 7) | ss/RA (n = 7) | SSc (n = 7) | SLE (n = 7) | RA (n = 7) | HC (n = 10) | |
|---|---|---|---|---|---|---|---|---|
Age, years, mean ± SD | 55.8 ± 13 | 63 ± 11 | 51 ± 16 | 61 ± 8 | 60.2 ± 7 | 48. ± 10 | 64.1. ± 9 | 56.6 ± 12.5 |
Disease duration, years, mean ± SD | 7.9 ± 4.2 | 12 ± 7 | 12 ± 9 | 10 ± 7 | 10.4 ± 8 | 11 ± 8 | 9.4 ± 8 | N/A |
Anti-Ro/SSA- and/or anti-La/SSB-positive, n | 9 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
ANA-positive, n | 6 | 7 | 7 | 1 | 7 | 7 | 2 | 0 |
RF-positive, n | 5 | 0 | 0 | 6 | 0 | 0 | 4 | 0 |
Focus score ≥1, n | 6 | 0 | 0 | 0 | N/A | N/A | N/A | 0 |
UWS <1.5 ml/15 minutes, n | 9 | 7 | 7 | 7 | 0 | 0 | 0 | 0 |
Schirmer test result <5 mm/5 minutes, n | 9 | 7 | 7 | 7 | 0 | 0 | 0 | 0 |
Xerostomia, n | 9 | 7 | 7 | 7 | 0 | 0 | 0 | 0 |
Xerophthalmia, n | 9 | 7 | 7 | 7 | 0 | 0 | 0 | 0 |